Acute viral encephalitis

New England Journal of Medicine

Volumn 379, Issue 6, 2018, Pages 557-566

  Tyler, Kenneth L ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; CHEMOKINE RECEPTOR; DEXAMETHASONE; IMMUNOGLOBULIN; MINOCYCLINE; RETINOIC ACID INDUCIBLE PROTEIN I; TOLL LIKE RECEPTOR; VALACICLOVIR; VIRUS ANTIBODY; ANTIVIRUS AGENT;

ADAPTIVE IMMUNITY; ADENOVIRUS INFECTION; ALPHAVIRUS; BUNYAVIRIDAE; CEREBROSPINAL FLUID ANALYSIS; COLTIVIRUS; CONTROLLED STUDY; DENGUE VIRUS; DISEASE PREDISPOSITION; DOUBLE BLIND PROCEDURE; EEG ABNORMALITY; ENCEPHALITIS; FEVER; FLAVIVIRUS; HEALTH CARE COST; HEREDITY; HERPES SIMPLEX VIRUS; HOSPITALIZATION; HUMAN; HUMAN HERPESVIRUS 6; HUMAN HERPESVIRUS 7; INCIDENCE; INNATE IMMUNITY; MENTAL HEALTH; MONOTHERAPY; NEUROIMAGING; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NEXT GENERATION SEQUENCING; PLEOCYTOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SEIZURE; UNITED STATES; VIRUS ENCEPHALITIS; WEST NILE VIRUS; ZIKA VIRUS; ACUTE DISEASE; BRAIN; DIAGNOSTIC IMAGING; HERPES SIMPLEX ENCEPHALITIS; NUCLEAR MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION; VIROLOGY;

ACUTE DISEASE; ACYCLOVIR; ANTIVIRAL AGENTS; BRAIN; ENCEPHALITIS, HERPES SIMPLEX; ENCEPHALITIS, VIRAL; HUMANS; MAGNETIC RESONANCE IMAGING; POLYMERASE CHAIN REACTION;

EID: 85051437823     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMra1708714     Document Type: Review

References (57)

1. Venkatesan A, Tunkel AR, Bloch KC, et al. Case definitions, diagnostic algo-rithms, and priorities in encephalitis: consensus statement of the International Encephalitis Consortium. Clin Infect Dis 2013;57:1114-28.
2. George BP, Schneider EB, Venkatesan A. Encephalitis hospitalization rates and inpatient mortality in the United States, 2000-2010. PLoS One 2014; 9(9): e104169.
3. Vora NM, Holman RC, Mehal JM, Steiner CA, Blanton J, Sejvar J. Burden of encephalitis-associated hospitalizations in the United States, 1998-2010. Neurology 2014;82:443-51.
4. Tunkel AR, Glaser CA, Bloch KC, et al. The management of encephalitis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008;47: 303-27.
5. Salimi H, Cain MD, Klein RS. Enceph-alitic arboviruses: emergence, clinical presentation, and neuropathogenesis. Neuro-therapeutics 2016;13:514-34.
6. Montgomery RR. Age-related altera-tions in immune responses to West Nile virus infection. Clin Exp Immunol 2017; 187:26-34.
7. Moraru M, Cisneros E, Gómez-Lozano N, et al. Host genetic factors in susceptibility to herpes simplex type 1 virus infection: contribution of polymorphic genes at the interface of innate and adaptive immunity. J Immunol 2012; 188: 4412-20.
8. Taylor KG, Woods TA, Winkler CW, Carmody AB, Peterson KE. Age-dependent myeloid dendritic cell responses mediate resistance to La Crosse virus-induced neurological disease. J Virol 2014; 88: 11070-9.
9. Long D, Deng X, Singh P, Loeb M, Lauring AS, Seielstad M. Identification of genetic variants associated with susceptibility to West Nile virus neuroinvasive disease. Genes Immun 2016; 17: 298-304.
10. Crosslin DR, Carrell DS, Burt A, et al. Genetic variation in the HLA region is associated with susceptibility to herpes zoster. Genes Immun 2015; 16: 1-7.
11. Qian F, Thakar J, Yuan X, et al. Im-mune markers associated with host susceptibility to infection with West Nile virus. Viral Immunol 2014; 27: 39-47.
12. Qian F, Goel G, Meng H, et al. Sys-tems immunology reveals markers of susceptibility to West Nile virus infection. Clin Vaccine Immunol 2015; 22: 6-16.
13. Ignatieva EV, Igoshin AV, Yudin NS. A database of human genes and a gene network involved in response to tick-borne encephalitis virus infection. BMC Evol Biol 2017;17:Suppl 2:259.
14. Mickiene A, Pakalniene J, Nordgren J, et al. Polymorphisms in chemokine receptor 5 and Toll-like receptor 3 genes are risk factors for clinical tick-borne encephalitis in the Lithuanian population. PLoS One 2014;9(9):e106798.
15. Lim JK, McDermott DH, Lisco A, et al. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 2010; 201: 178-85.
16. Mørk N, Kofod-Olsen E, Sørensen KB, et al. Mutations in the TLR3 signaling pathway and beyond in adult patients with herpes simplex encephalitis. Genes Immun 2015;16:552-66.
17. Verma R, Bharti K. Toll like receptor 3 and viral infections of nervous system. J Neurol Sci 2017;372:40-8.
18. Sironi M, Peri AM, Cagliani R, et al. TLR3 mutations in adult patients with herpes simplex virus and varicella-zoster virus encephalitis. J Infect Dis 2017; 215: 1430-4.
19. Lim JK, Lisco A, McDermott DH, et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009; 5(2): e1000321.
20. Steiner I, Budka H, Chaudhuri A, et al. Viral meningoencephalitis: a review of diagnostic methods and guidelines for management. Eur J Neurol 2010; 17(8): 999-1009.
21. Solomon T, Michael BD, Smith PE, et al. Management of suspected viral enceph-alitis in adults-Association of British Neurologists and British Infection Association National Guidelines. J Infect 2012; 64:347-73.
22. Whitley RJ, Soong S-J, Linneman C Jr, Liu C, Pazin G, Alford CA. Herpes simplex encephalitis. JAMA 1982;247:317-20.
23. Chow FC, Glaser CA, Sheriff H, et al. Use of clinical and neuroimaging characteristics to distinguish temporal lobe herpes simplex encephalitis from its mimics. Clin Infect Dis 2015; 60: 1377-83.
24. Glaser CA, Honarmand S, Anderson LJ, et al. Beyond viruses: clinical profiles and etiologies associated with encephalitis. Clin Infect Dis 2006; 43: 1565-77.
25. Beattie GC, Glaser CA, Sheriff H, et al. Encephalitis with thalamic and basal ganglia abnormalities: etiologies, neuroimag-ing, and potential role of respiratory viruses. Clin Infect Dis 2013; 56: 825-32.
26. Xu GJ, Kula T, Xu Q, et al. Compre-hensive serological profiling of human populations using a synthetic human vi-rome. Science 2015;348:aaa0698.
27. Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter evaluation of BioFire FilmArray meningitis/encephalitis panel for detection of bacteria, viruses and yeast in cerebrospinal fluid specimens. J Clin Microbiol 2016;54:2251-61.
28. Simner PJ, Miller S, Carroll KC. Understanding the promises and hurdles of metagenomic next-generation sequencing as a diagnostic tool for infectious diseases. Clin Infect Dis 2018; 66: 778-88.
29. Brown JR, Bharucha T, Breuer J. En-cephalitis diagnosis using metagenomics: application of next generation sequencing for undiagnosed cases. J Infect 2018; 76: 225-40.
30. Salter SJ, Cox MJ, Turek EM, et al. Reagent and laboratory contamination can critically impact sequence-based micro-biome analyses. BMC Biol 2014; 12: 87.
31. Bastos MS, Coelho-Dos-Reis JG, Zauli DA, et al. Divergent cerebrospinal fluid cytokine network induced by non-viral and different viral infections on the central nervous system. BMC Infect Dis 2015; 15:345.
32. Kothur K, Wienholt L, Mohammad SS, et al. Utility of CSF cytokine/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis. PLoS One 2016;11(8):e0161656.
33. Stahl JP, Mailles A, De Broucker T. Herpes simplex encephalitis and management of acyclovir in encephalitis patients in France. Epidemiol Infect 2012; 140: 372-81.
34. Gnann JW Jr, Sköldenberg B, Hart J, et al. Herpes simplex encephalitis: lack of clinical benefit of long-term valacyclovir therapy. Clin Infect Dis 2015; 61: 683-91.
35. Kimberlin DW, Lin CY, Jacobs RF, et al. Safety and efficacy of high-dose intravenous acyclovir in the management of neonatal herpes simplex virus infections. Pediatrics 2001;108:230-8.
36. Maras Genç H, Uyur Yalçin E, Sayan M, et al. Clinical outcomes in children with herpes simplex encephalitis receiving steroid therapy. J Clin Virol 2016; 80: 87-92.
37. Ramos-Estebanez C, Lizarraga KJ, Merenda A. A systematic review on the role of adjunctive corticosteroids in herpes simplex virus encephalitis: is timing critical for safety and efficacy? Antivir Ther 2014;19:133-9.
38. Kumar R, Basu A, Sinha S, et al. Role of oral minocycline in acute encephalitis syndrome in India-a randomized controlled trial. BMC Infect Dis 2016; 16: 67.
39. Solomon T, Dung NM, Wills B, et al. Interferon alfa-2a in Japanese encephalitis: a randomised double-blind placebo-controlled trial. Lancet 2003; 361: 821-6.
40. Rayamajhi A, Nightingale S, Bhatta NK, et al. A preliminary randomized double blind placebo-controlled trial of intravenous immunoglobulin for Japanese encephalitis in Nepal. PLoS One 2015; 10(4): e0122608.
41. Hart J Jr, Tillman G, Kraut MA, et al. West Nile virus neuroinvasive disease: neurological manifestations and prospective longitudinal outcomes. BMC Infect Dis 2014;14:248.
42. Tzannou I, Papadopoulou A, Naik S, et al. Off-the-shelf virus-specific T cells to treat BK virus, human herpesvirus 6, cyto-megalovirus, Epstein-Barr virus, and ade-novirus infections after allogeneic hema-topoietic stem-cell transplantation. J Clin Oncol 2017;35:3547-57.
43. Davies SI, Muranski P. T cell therapies for human polyomavirus diseases. Cyto-therapy 2017;19:1302-16.
44. Leibovitch EC, Jacobson S. Vaccina-tions for neuroinfectious disease: a global health priority. Neurotherapeutics 2016; 13:562-70.
45. Upreti SR, Lindsey NP, Bohara R, et al. Updated estimation of the impact of a Japanese encephalitis immunization program with live, attenuated SA 14-14-2 vaccine in Nepal. PLoS Negl Trop Dis 2017; 11(9): e0005866.
46. Streng A, Grote V, Rack-Hoch A, Liese JG. Decline of neurologic varicella complications in children during the first seven years after introduction of universal varicella vaccination in Germany, 2005-2011. Pediatr Infect Dis J 2017; 36: 79-86.
47. Pringle KD, Burke RM, Steiner CA, Parashar UD, Tate JE. Trends in rate of seizure-associated hospitalizations among children <5 years old before and after rotavirus vaccine introduction in the United States, 2000-2013. J Infect Dis 2018; 217:581-8.
48. Singh TD, Fugate JE, Rabinstein AA. The spectrum of acute encephalitis: causes, management, and predictors of outcome. Neurology 2015;84:359-66.
49. Singh TD, Fugate JE, Hocker S, Wij-dicks EFM, Aksamit AJ Jr, Rabinstein AA. Predictors of outcome in HSV encephalitis. J Neurol 2016; 263: 277-89.
50. Erdem H, Cag Y, Ozturk-Engin D, et al. Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis. Antimicrob Agents Chemother 2015;59:3084-9.
51. Sunwoo JS, Lee ST, Jung KH, et al. Clinical characteristics of severe Japanese encephalitis: a case series from South Korea. Am J Trop Med Hyg 2017; 97: 369-75.
52. Raschilas F, Wolff M, Delatour F, et al. Outcome of and prognostic factors for herpes simplex encephalitis in adult patients: results of a multicenter study. Clin Infect Dis 2002;35:254-60.
53. Poissy J, Wolff M, Dewilde A, et al. Factors associated with delay to acyclovir administration in 184 patients with herpes simplex virus encephalitis. Clin Microbiol Infect 2009; 15: 560-4.
54. Hughes PS, Jackson AC. Delays in ini-tiation of acyclovir therapy in herpes simplex encephalitis. Can J Neurol Sci 2012; 39:644-8.
55. Benson PC, Swadron SP. Empiric acy-clovir is infrequently initiated in the emergency department to patients ultimately diagnosed with encephalitis. Ann Emerg Med 2006;47:100-5.
56. Kneen R, Jakka S, Mithyantha R, Rior-dan A, Solomon T. The management of infants and children treated with aciclovir for suspected viral encephalitis. Arch Dis Child 2010;95:100-6.
57. Bell DJ, Suckling R, Rothburn MM, et al. Management of suspected herpes simplex virus encephalitis in adults in a U.K. teaching hospital. Clin Med (Lond) 2009; 9: 231-5.